Xilio Therapeutics (XLO) Times Interest Earned (2020 - 2026)
Xilio Therapeutics (XLO) reported Times Interest Earned of -$742.74 for Q1 2026, down 216.38% on a YoY basis from $638.21 in Q1 2025, and down 69.43% sequentially from -$438.37 in Q4 2025.
Xilio Therapeutics (XLO) Times Interest Earned (2020 - 2026) Analysis & Trends
Xilio Therapeutics (XLO) has 7 years of Times Interest Earned data on file, last reported at -$742.74 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned fell 216.38% year-over-year to -$742.74; the trailing twelve-month figure through Mar 2026 stood at -$2223.3 (down 130.35% YoY), and the FY2025 full-year result was -$0.33, up 37.84% from the prior year.
- Times Interest Earned declined to -$742.74 in Q1 2026, from -$438.37 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$16.74 in Q4 2023 to a low of -$742.74 in Q1 2026.
- A 5-year average of -$191.23 and a median of -$106.12 in 2022 frame the typical range for Times Interest Earned.
- Peak annual rise in Times Interest Earned reached 90.55% in 2022, while the deepest fall reached 9030.53% in 2022.
- Tracing XLO's Times Interest Earned over 5 years: stood at -$18.47 in 2022, then increased by 9.39% to -$16.74 in 2023, then slumped by 188.7% to -$48.33 in 2024, then sank by 807.04% to -$438.37 in 2025, then sank by 69.43% to -$742.74 in 2026.
- Business Quant data shows XLO's Times Interest Earned at -$742.74 in Q1 2026, -$438.37 in Q4 2025, and -$28.37 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -157.58 |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 7.60 |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -0.38 |
| 10 | Xilio Therapeutics | 148.60 Mn | -1.70 Mn | - | -742.74 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -742.74 |
| Dec 31, 2025 | -438.37 |
| Sep 30, 2025 | -28.37 |
| Jun 30, 2025 | -368.36 |
| Mar 31, 2025 | -234.76 |
| Dec 31, 2024 | -48.33 |
| Sep 30, 2024 | -149.11 |
| Jun 30, 2024 | -84.02 |
| Mar 31, 2024 | -55.69 |
| Dec 31, 2023 | -16.74 |
| Sep 30, 2023 | -403.74 |
| Jun 30, 2023 | -261.25 |
| Mar 31, 2023 | -112.56 |
| Dec 31, 2022 | -18.47 |
| Sep 30, 2022 | -92.26 |
| Jun 30, 2022 | -89.93 |
| Mar 31, 2022 | -106.12 |
| Dec 31, 2021 | -195.56 |
| Sep 30, 2021 | -1.01 |
| Jun 30, 2021 | -230.07 |